In reply [23]

Journal of Clinical Oncology

Volumn 23, Issue 28, 2005, Pages 7250-

  Levine, Mark N ^a   Lee, Agnes Y Y ^a   Kakkar, Ajay K ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

CANCER MORTALITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; LETTER; LONG TERM CARE; MEDICAL LITERATURE; METASTASIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 33847063945     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.1527     Document Type: Letter

References (6)

1. Prandoni P, Lensing AWA, Piccioli A, et al: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484-3488, 2002
2. Hutten BA, Prins MH, Gent M, et al: Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis. J Clin Oncol 18:3078-3083, 2000
3. Lee AY, Levine MN, Baker RI, et al: Low molecular weight heparin versus a coumarin for prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146-153, 2003
4. Lee AYY, Rickles FR, Julian JA, et al: Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23:2123-2129, 2005
5. Collen A, Smorenburg SM, Peters E, et al: Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 60:6196-6200, 2000
6. Kakkar AK, Levine MN: Thrombosis and cancer: Implications beyond Trousseau. J Thrombo Haemost 2:1261-1262, 2004